The global aesthetic industry is undergoing rapid transformation. From injectables to laser treatments, and from cosmeceuticals to holistic skin rejuvenation protocols, innovation is booming. But with innovation comes responsibility: scientific validation is essential to meet growing regulatory demands and consumer expectations.
Pre/post-treatment studies are central to demonstrating the efficacy of aesthetic interventions. By comparing baseline and post-intervention data, they provide measurable insights across botulinum toxin, dermal fillers, chemical peels, and non-invasive rejuvenation techniques. At Eurofins C&PC, we design these studies with precision, integrating both quantitative and qualitative endpoints, including 2D and 3D imaging, biophysical measurements, and patient-reported outcomes.
Our studies follow standardised protocols, sometimes including Phase I to IV trials, to detect significant changes in skin condition. Objective measurements (hydration, elasticity, pigmentation) are combined with expert and patient assessments, while validated imaging systems and centralised quality control ensure reliable, reproducible results. This approach applies to a wide range of indications, from non-surgical skin rejuvenation and scar reduction to pigmentation disorders, hyperhidrosis, epilation, and lipolysis techniques.
With access to a worldwide network of dermatologists and key opinion leaders, Eurofins C&PC ensures studies are tailored to each product’s mechanism of action, enabling fast recruitment and high-quality data. In addition to our clinical expertise, we also provide dedicated ex vivo models for laser-based interventions, allowing profound understanding of a product's effects on human skin and fine tuning of the product's concept before moving into volunteer studies.
In a fast-moving aesthetic landscape, we bring scientific rigour and clarity, helping innovators move from concept to clinical proof with confidence and impact.